DUBLIN, Eire, July 22, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical firm engaged within the commercialization and growth of revolutionary anti-infective brokers to deal with severe infections, at present introduced that it’s going to report its second quarter monetary outcomes together with latest firm highlights after the shut of the U.S. monetary markets on Thursday, August 5, 2021. Nabriva’s administration will host a convention name at 4:30 p.m. ET to debate the monetary outcomes and up to date company highlights.
The dial-in quantity for the convention name is 866-811-8671 for home members and 409-981-0874 for worldwide members, with Convention ID #6299497. A reside webcast of the convention name may be accessed by way of the “Buyers” tab on the Nabriva Therapeutics web site at www.nabriva.com. A replay will probably be obtainable on this web site shortly after conclusion of the occasion for 90 days.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical firm engaged within the commercialization and growth of revolutionary anti-infective brokers to deal with severe infections. Nabriva Therapeutics acquired U.S. Meals and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the primary systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics can be creating CONTEPO™ (fosfomycin) for injection, a possible first-in-class epoxide antibiotic for sophisticated urinary tract infections (cUTI), together with acute pyelonephritis. Nabriva entered into an unique settlement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, promote and distribute SIVEXTRO® (tedizolid phosphate) in america and sure of its territories.
Any statements on this press launch about future expectations, plans and prospects for Nabriva Therapeutics, together with however not restricted to statements concerning the potential of Nabriva Therapeutics to lift consciousness of XENLETA and SIVEXTRO, drive prescription demand progress and drive top-line gross sales progress, the potential advantages to sufferers of SIVEXTRO and XENLETA, the market alternative for SIVEXTRO and XENLETA, the provision of SIVEXTRO by way of main U.S. specialty wholesalers, the affect on Nabriva Therapeutics’ reported income from anticipated gross sales of SIVEXTRO, the sufficiency of its money sources and different statements containing the phrases “anticipate,” “consider,” “estimate,” “anticipate,” “intend,” “might,” “plan,” “predict,” “venture,” “goal,” “potential,” “possible,” “will,” “would,” “may,” “ought to,” “proceed,” and related expressions, represent forward-looking statements throughout the that means of The Non-public Securities Litigation Reform Act of 1995. Precise outcomes might differ materially from these indicated by such forward-looking statements because of numerous necessary elements, together with: Nabriva Therapeutic’s potential to adjust to its obligations underneath its mortgage settlement with Hercules, Nabriva Therapeutic’s potential to take care of the circumstances underneath the distribution settlement to completely distribute and promote SIVEXTRO, together with its potential to take care of a business infrastructure ample to advertise and distribute SIVEXTRO, the extent of enterprise interruptions ensuing from the an infection inflicting the COVID-19 outbreak or related public well being crises, the flexibility to retain and rent key personnel, the provision of sufficient further financing on acceptable phrases or in any respect and such different necessary elements as are set forth in Nabriva Therapeutics’ annual and quarterly studies and different filings on file with the SEC. As well as, the forward-looking statements included on this press launch signify Nabriva Therapeutics’ views as of the date of this press launch. Nabriva Therapeutics anticipates that subsequent occasions and developments might trigger its views to alter. Nevertheless, whereas Nabriva Therapeutics might elect to replace these forward-looking statements sooner or later sooner or later, it particularly disclaims any obligation to take action. These forward-looking statements shouldn’t be relied upon as representing Nabriva Therapeutics’ views as of any date subsequent to the date of this press launch.
Nabriva Therapeutics plc